Infliximab in rheumatoid arthritis.
Moreland
Larry
L
Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, 1813 6th Avenue South, MEB 625, Birmingham, AL 35294, USA.
D000284:Administration, Oral; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D001172:Arthritis, Rheumatoid / Q000175:diagnosis / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000069285:Infliximab; D007279:Injections, Subcutaneous; D007391:International Cooperation; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage*; D010147:Pain Measurement; D012720:Severity of Illness Index; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D000069285:Infliximab; D008727:Methotrexate